In conclusion, paclitaxel-coated balloons do provide benefit at 6 months, but this benefit may not last.
PTA is not an effective treatment strategy for SFA-ISR, especially for longer lesions. Furthermore, these data suggest that PTA has outrun its usefulness as a comparator for SFA-ISR trials from an ethical standpoint. Any further studies should use an Food and Drug Administration-approved device as the comparator. There is no single "default strategy" for the treatment of SFA-ISR, allowing the practitioner to use their best judgment to make this on-table decision.
